Statement from New England Compounding Center

FRAMINGHAM, Mass.--()--The following is a statement from New England Compounding Center:

“New England Compounding Center (NECC) is working closely with the Massachusetts Board of Pharmacy, the Centers for Disease Control and the U.S. Food and Drug Administration on their investigation into the cause of infection in patients who received injections of methylprednisolone acetate. As part of this process, NECC has initiated a series of recalls encompassing all methylprednisolone acetate products - as well as other injectable medications - distributed from our facility in Framingham, Massachusetts. We also understand the FDA – as a precautionary measure - has suggested to medical professionals that they do not use any NECC products at this time, although there is no indication of any potential issues with other products. As previously announced, we have voluntarily suspended operations while we assist authorities in this investigation. The fatalities and illnesses confirmed today by the CDC and FDA are tragic. The thoughts and prayers of everyone employed by NECC are with those who have been affected.”

Contacts

O'Neill and Associates
Krista Robinson, 617-646-1066
contact@oneillandassoc.com

Release Summary

Statement from New England Compounding Center.

Contacts

O'Neill and Associates
Krista Robinson, 617-646-1066
contact@oneillandassoc.com